Author Archives for kyle_fifteen

SYNthesis med chem, Cytopia and Ojjaara

September 21, 2023 9:24 am Published by Leave your thoughts

In the late 2000’s, a small Australian biotech – Cytopia - discovered a molecule capable of selective inhibition of JAK1/2 and activin A receptor, type I (ACVR1). Since that time, it has passed through 4 companies, both big and small who variously advanced or failed the compound, finally landing at GSK for $1.9B dollars.

SYNthesis med chem supporting a variety of Drug Discovery events through the end of 2023 and into 2024

September 1, 2023 9:00 am Published by Leave your thoughts

Our Discovery Project Leaders and Business Development teams will be present at a number of events at the end of 2023 and in the first half of 2024, meeting with existing and new collaborators and keeping up-to-date with the latest therapeutic and technology developments to best support our clients’ programs through the Discovery process.